1Oka J,Imamura M,Hatta E,et al.Carrier-mediated norepinephrine release and reperfusion arrhythmias induced by protracted ischemia inisolated perfused guinea pig hearts:effect of presynaptic modulation by α2-adrenoceptor in mild hypothermic ischemia[J].J Pharmacol Exp Ther,2002,303(2):681 -687.
2Levi R,Silker RB,Maokins C.J,et al.Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release[J].Int Immunopharmacol,2002,2(13-14):1965-1973.
3Silver RB,Poonwasi KS,Seyedi N.Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings[J].PNAS,2002,99 (1):501-506.
4Hovea MT,Cees JA,Echteld V,et al.Limited effects of post-ischemic NHE blockade on[Na +] i and phi in rat hearts explain its lack of cardioprotection[J].Cardiovas res,2004,61 (3):522-529.
5Seyedi N,Koyama M,Mackins CJ,et al.Ischemia promotes renin activation and angiotensin formation in sympathetic nerve terminals i solated from the human heart:contribution to carrier -mediated norepinephrine release[J].J Pharmacol Exp Ther,2002,302 (2):539-544.
6Richardt D,Wolfrum S,Buttner C,et al.Effect of ACE inhibitor ramiprilat and AT1 receptor antagonist candesartan on cardiac norepinephrine release:comparison between ischemic and nonischemic conditions[J].J Cardiovasc Pharmacol,2004,40 (4):641-646.
7Lameris TW,Zeeuw DS,Duncker DJ,et al.Exogenous angiotensin Ⅱ does not facilitate norepinephrine release in the heart[J].Hypertension,2002,40 (4):491-497.
8Xiao XH,Allen DG.The role of endogenous angiotensin Ⅱ in ischemia,reperfusion and preconditioning of the isolated rat heart[J].Pflugers Arch,2003,445 (6):643-650.
9Masereel B,Pochet L,Laeckmann D.An overview of inhibitors of Na +/H + exchanger[J].Eur J Med Chem,2003,38 (6):547 -554.
10Koyama M,Heerdt PM,Levi R,et al.Increased severity of reperfusion arrhythmias in mouse hearts lacking histamine H3-receptors[J].Biochem Biophys Res Commun,2003,306(3):792 -796.
二级参考文献6
1Faber TS, Zehender M, Krahnefeld O, et al. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study[J]. J Am Coll Cardiol, 1997, 29(3): 561-567.
2Mastropasqua F, Totaro P, Massari F, et al. Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms[J]. Cardiologia, 1998, 43(6): 617-623.
3Koller B, Franz MR. New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart[J]. J Cardiovasc Pharmacol, 1994, 24(5): 753-760.
4Takahashi N, Ito M, Ishida S, et al. Electrophysiological effects of SD-3212, a novel antiarrhythmic agent, on rabbit hearts in vivo and in vitro[J]. J Cardiovasc Pharmacol, 1995, 25(6): 1006-1011.
5Yin H, Sherif N, Caref EB, et al. Actions of lidocaine on reentrant ventricular rhythms in the subacute myocardial infarction period in dogs[J]. Am J Physiol, 1997, 272(1 Pt 2): H299-H300.
6Bardou AL, Auger PM, Achour S, et al. Effect of myocardial infarction and ischemia on induction of cardiac reentries and ventricular fibrillation[J]. Acta Biotheor, 1995,43(4): 363-372.
